WO2005100983A1 - 悪性腫瘍の検査方法 - Google Patents
悪性腫瘍の検査方法 Download PDFInfo
- Publication number
- WO2005100983A1 WO2005100983A1 PCT/JP2005/006634 JP2005006634W WO2005100983A1 WO 2005100983 A1 WO2005100983 A1 WO 2005100983A1 JP 2005006634 W JP2005006634 W JP 2005006634W WO 2005100983 A1 WO2005100983 A1 WO 2005100983A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor
- test method
- erbb
- her2
- cell membrane
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4725—Mucins, e.g. human intestinal mucin
Definitions
- the present invention relates to a method for examining a malignant tumor, and relates to a treatment strategy, a prognosis prediction, and a prediction of a therapeutic effect of a treatment for inhibiting the function of a cell growth factor receptor receptor by a humanized monoclonal antibody. It relates to an inspection method.
- the molecular target therapeutic agent for cancer has attracted attention as a new type of anticancer agent in comparison with the conventional cell target therapeutic agent.
- drugs having an inhibitory effect on signal transduction are attracting attention.
- the c-erbB-2 oncogene encodes a protein (HER2 / c-erbB-2) having a molecular weight of 185 kDa and having a receptor structure penetrating the cell membrane (Non-patent Documents 1 and 2).
- HER2 / c-erbB-2 is a tyrosine kinase type receptor and belongs to the EGFR family having a similar structure to the human epidermal growth factor receptor (EGFR) gene.
- the extracellular domain of HER2 / C-erbB-2 has a receptor structure, and extracellular ligands bind to this extracellular domain, activating tyrosine kinase in the intracellular domain.
- Non-Patent Document 3 This causes autophosphorylation of HER2 / C-erbB-2 and phosphorylation of a substance that interacts with HER2 / c-erbB-2 in the cell, transmitting a proliferation signal to the cell surface force nucleus, It is thought to be involved in cell proliferation and sorting! / Puru (Non-Patent Document 3).
- the HER2 / c-erbB-2 protein is overexpressed in various human tumors. Particularly in breast cancer, patients with overexpression of the c-erbB-2 gene or its protein have a poor prognosis, and the c-erbB-2 gene is one of the important factors in diagnosing, prognosing, or deciding treatment.
- Trastuzumab (Herceptin is a humanized monoclonal antibody that specifically binds to the HER2 / c-erbB-2 protein.
- HER2 / c-erbB-2 protein is overexpressed and specifically binds to tumor cells. This inhibits HER2 / c-erbB-2 protein receptor function and inhibits signal transduction, thereby inhibiting tumor cell growth. Therefore, trastudsumab (Hersep Identification of patients to be treated with tin requires overtesting of HER2 / c-erbB-2 protein overexpression in cancer tissues or the status of c-erbB-2 gene amplification (non-patent Reference 4).
- 3+ was evaluated as being useful for treatment with trastuzumab (Herceptin, but 2+ was evaluated. In other words, 3+ has a certain effect on treatment with trastuzumab (noceptin 3 ⁇ 4 ft mm ) Force 2+ does not necessarily have trastuzumab (treatment with herceptin is not effective in many cases) In contrast, treatment with trastuzumab (Herceptin is said to be effective at a certain rate if the FISH method is positive.
- Immunohistochemical staining of tissue sections has been shown to be a reliable method for evaluating changes in protein in heterologous tissues.
- Immunohistochemistry is a method in which an antibody is used as a probe, and an antigen present on cells is visualized and examined in situ, generally by a coloring method or a fluorescence method.
- FISH method fluorescence in situ hybridization method
- Mucin 4 is a HER2 / c-erbB-2 conjugate in the cell membrane (Non-Patent Document 6). Furthermore, when HER2 / c-erbB-2 is expressed and MUC4 / sialomtin is transfected into cells without MUC4 / sialomtin, the tyrosine at position 1248 of HER2 / C-erbB-2 is phosphorylated. Sialomtin is also involved in the phosphorylation of HER2 / c-erbB-2 (Non-Patent Document 6).
- Non-patent document l Biochem. Et Biophys. Acta, 1198, 165-184 (1994)
- Non-Patent Document 2 Oncogene, 9, 2109-2123 (1994)
- Non-patent Document 3 Brit.J. Cancer, 72, 1259-1266 (1995)
- Non-Patent Document 4 Science, 235, 177-182 (1987)
- Non-Patent Document 5 J. Pathology, 199, 411-417 (2003)
- Non-Patent Document 6 J. Biol. Chem., 278, 30142-30147 (2003)
- the problem to be solved by the present invention is to provide a new test method for accurately determining the efficacy of a treatment for an anticancer drug targeting a receptor for a tumor-related factor.
- the present inventor is a receptor for a tumor-related factor.
- trastuzumab a cancer drug targeting HER2 / c-erbB-2 (with Herceptin The examination method to judge the efficacy accurately was examined.
- trastuzumab (Norceptin®)
- overexpression of HER2 / C-erbB-2 is currently examined by immunohistochemistry, FISH, and the like.
- FISH fluorescence in situ hybridization
- the protein is positive only when the protein is stained in the cell membrane, and the stainability only in the cytoplasm is negative.
- the overexpressed HER2 / c-erbB-2 needs to be functionally present as a receptor on the cell membrane.
- trastuzumab (nodeceptin) was used for cancers overexpressing HER2 / c-erbB_2.
- the present invention consists of the following:
- test method performed when an anticancer drug targeting a tumor-related factor receptor is administered. In addition to testing for the receptor gene and Z or the expression product of the gene, the test method is performed on the cell membrane surface and Z or in the cell membrane.
- a method for judging the usefulness of anticancer drug treatment characterized by examining the gene of a substance that interacts with a receptor and the expression product of Z or the gene by using the method.
- test method according to any one of the above items 1 to 4, wherein the substance that interacts with the receptor on the cell membrane surface and Z or in the cell membrane is a glycoprotein.
- the present invention is a test method for determining the usefulness of anticancer drug treatment, which is performed when administering an anticancer drug targeting a tumor-related factor receptor.
- the method is characterized by examining the gene of the substance that interacts with the receptor on the cell membrane surface and Z or within the cell membrane, and Z or the expression product of the gene.
- a tumor is a tissue in a living body that is a cell derived from the individual, but that breaks the harmony of the individual as a whole and undergoes excessive growth according to its own discipline without any control.
- a tumor-related factor refers to a factor involved in tumor formation.
- cytoforce is preferable.
- Cytokines include, but are not limited to, growth factors, interferons (IFN), tumor necrosis factor (TNF), interleukins (IL), and the like. Among the cytokins, growth factors are more preferred. Growth factors include, but are not limited to, epidermal growth factor, hepatocyte growth factor, fibroblast growth factor, platelet-derived growth factor, insulin-like growth factor, vascular endothelial growth factor, and the like.
- the receptor is a structure composed of a protein for allowing cells to recognize a specific chemical substance. Chemical messengers, various cell growth factors, etc., exhibit efficient uptake into cells and signal transmission into cells by binding to specific receptors on the cell membrane. .
- the receptor for the tumor-associated factor epidermal growth factor receptor, which is preferred by cell growth factor receptor, and receptors belonging to the family are more preferable.
- HER2 / c-erbB-2 is a preferred example of a receptor belonging to the epidermal growth factor receptor family.
- the substance that interacts with the receptor on the cell membrane surface and Z or in the cell membrane refers to a substance that interacts with the receptor on the cell membrane surface and Z or in the cell membrane and plays a role in expressing or enhancing the function of the receptor.
- mucins which are preferably glycoproteins, are more preferable. Mucinous Some are known as cancer antigens.
- MUC4 is known to interact with the HER2 / c-erbB-2 protein in cells, and is a preferred example.
- Anticancer agents are a general term for drugs used for malignant tumors, and suppress the expression of oncogenes and the function of Z or expression products.
- the anticancer agent of the present invention targets a tumor-associated factor receptor.
- Examples of such anticancer agents include cancer molecular target therapeutic agents.
- drugs that inhibit signal transduction are typical, and examples include so-called tyrosine kinase inhibitors.
- Such compounds include, for example, benzylidene malon-tolyl derivatives (Japanese Patent Application Laid-Open No.
- HEI 2 (1996) such as microorganism-derived erbstatin, lavendastin (Lavendustin), herbimycin A (Herbimycin A), and genistein (Genistein). No. 138238, Journal of Medical Chemistry, 32, 2344 (1989); 34,1896 (1991)), a cyanocinnamic acid amide derivative (JP-A-63-222153), 3,5 diisopropyl 4-hydroxy Styrene derivatives (Japanese Patent Application Laid-Open No. 62-39522), 3,5-deepyl-4-hydroxystyrene derivatives (Japanese Patent Application Laid-Open No. 62-39523), and abstatin analogues (Japanese Patent Application Laid-Open No. 62-277347) Gazette).
- humanized monoclonal antibodies more preferably antibodies against products involved in the signal transduction system, are more preferred.
- Products involved in the signal transduction system include each receptor, and an antibody against each receptor is exemplified.
- As a typical receptor As a typical receptor,
- trastuzumab nodeceptin
- ZD1839 Iressa
- STI-571 and the like are exemplified.
- ZD1839 (Iressa ⁇ ft ⁇ ) is an inhibitor of tyrosine kinase activity of EGFR
- STI-571 is an inhibitor of tyrosine kinase activity of BCR-Abl and c-kit.
- Cancer refers to a physiological condition in mammals that is typically characterized by unregulated cell growth.
- examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, melanoma and leukemia.
- cancers include squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous lung Carcinoma, peritoneal cancer, hepatocellular carcinoma, gastrointestinal cancer, spleen cancer, glioblastoma, cervical cancer, non-small cell lung cancer, ovarian cancer, liver cancer, bladder cancer, liver cancer, breast cancer, colon cancer Includes colorectal, endometrial or uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, spawning ovary cancer, thyroid cancer, and various types of head and neck cancer.
- Examples of the gene encoding a product involved in the signal transduction system include a gene which issues an instruction for canceration when a cell becomes cancerous.
- Such genes include, but are not limited to, sis, int-2, hst with growth factor function, erbB, erbB-2 / neu, ros, & is, with receptor tyrosine kinase function.
- kit ret, src, yes, fgr, lck, fts / fes, abl, non-receptor tyrosine kinase function c-raf with serine 'threon kinase function, other ras, bcl, int-1, crk And nuclear proteins such as myc, fos, jun, and erbA.
- substances that suppress the function of the gene or the function of the expression product are developed and used as pharmaceuticals.
- an antibody drug used as an antibody drug
- V. trusuzumab (Nepticeptin seffi) against HER2 / c-erbB-2, which is an erbB-2 / neu gene product, is a preferred example.
- tissue sample intends a population of similar cells obtained from a tissue of a subject or patient, preferably comprising nucleated cells having chromosomal material.
- the tissue sample may contain natural, essentially non-contaminating components such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, and the like.
- tissue samples used include, but are not limited to, breast, prostate, ovary, colon, lung, endometrium, stomach, salivary gland, or spleen.
- Tissue samples can be obtained in a variety of ways, including, but not limited to, surgical resection, aspiration, or biopsy. Tissues can be raw or frozen.
- the tissue sample can be fixed by conventional methods.
- the fixative is determined such that the tissue is stained histologically or otherwise analyzed.
- the length of the fixation depends on the size of the tissue sample and the fixative used.
- the tissue sample is first fixed, then dehydrated with an ascending series of alcohol, and embedded with noraffin or other sectioning media that allows the tissue sample to be sectioned. Yes! /, Section the tissue and allow the resulting section to be fixed.
- tissue samples It can be embedded and quenched in paraffin by conventional methods.
- the sample can be sectioned with mitochrome or the like. Once sectioned, the sections can be attached to slides in several standard ways.
- tissue sections are generally deparaffinized and rehydrated with water.
- Tissue sections can be deparaffinized by several conventional methods. For example, xylene and slow descending alcohols can be used.
- Methods for testing the gene and Z or an expression product of the gene include a genetic test and an immunological test. Furthermore, the present invention includes a combination of a genetic test method and an immunological test method, and a combination of another test method.
- the genetic test method is a method for testing gene amplification, and a conventional method such as a FISH method, an RT-PCR method, or Southern blotting is used.
- gene amplification contemplates the presence of one or more additional gene copies of the tumor antigen-encoding gene of the stained complement. Gene amplification can result in overexpression of the protein.
- the probe used for the genetic test may be an RNA or DNA oligonucleotide or a polynucleotide.
- the probe may have sufficient complementarity with the target nucleic acid sequence of interest such that stable specific binding occurs between the probe and the target nucleic acid probe.
- the degree of homology required for stable hybridization will vary depending on the stringency of the medium, the hybridization medium and the Z or wash medium. The choice of the probe depends on the nature of the target gene.
- the immunological test method is a method for testing a gene expression product with an antibody, and a conventional method such as an immunohistochemical method or an EIA method is used.
- Antibodies for use in immunoassays include, but are not limited to, monoclonal antibodies, polyclonal antibodies, and fragments thereof.
- the following method is an example of an immunohistological dyad staining method using an antibody that specifically recognizes HER2 / c-erbB-2;
- the section is washed with 0.1 M PBS three times for 5 minutes, and then incubated with a peroxidase-labeled secondary antibody at room temperature for 30 minutes.
- the section was washed three times for 5 minutes with 0.1 M PBS, and incubated with a DAB reaction solution (DAB tetrahydrochloride 10 mg, PBS 50 ml, 1.5% HO 1) for 3 to 10 minutes to develop color.
- DAB reaction solution DAB tetrahydrochloride 10 mg, PBS 50 ml, 1.5% HO
- the method of examining the gene of the receptor for tumor-associated factor and Z or the expression product of the gene may be used in addition to the gene of the receptor and Z or the expression product of the gene.
- the gene of the substance interacting with the receptor on the surface of the cell membrane and Z or within the cell membrane and the expression product of Z or the gene are detected in the test sample, it is useful for the treatment of anticancer drugs targeting the receptor. Can be determined.
- HER2 / c-erbB-2 is overexpressed not only in breast cancer but also in many cancers, only breast cancer has been practically used for treatment. This is due to the low effective rate of treatment for cancers other than breast cancer that highly express HER2 / c-erbB-2. In colorectal cancer, etc., the effect of HER2 / c-erbB_2 overexpression at high frequency Basically, MUC4 is negative in the epithelium of the colon, including tumors, and is unlikely to have a therapeutic effect. is there. However, some cancers of MUC4-positive organs highly express HER2 / c-erbB-2.
- trastuzumab For those cancers, select the cases that express both MUC4 and HER2 / c-erbB-2, and select trastuzumab (Herceptin treatment to determine the possibility of obtaining a high therapeutic effect. Therefore, the combined use of the MUC4 and HER2 / C-erbB-2 tests can broaden the indications for treatment with trastuzumab (Norceptin®).
- one embodiment of the present invention includes a reagent and a reagent kit that can be used in the test method of the present invention.
- Reagents and reagent kits may be provided in the form of an article of manufacture, the article of manufacture comprising a container, optionally a label and a package insert.
- trastuzumab Herceptin
- MUC4 the staining of MUC4 by immunohistochemistry
- HER2 / c-erbB_2 detected by immunohistochemical staining described above in the tissues of breast cancer patients.
- trastuzumab (Herceptin 3 ⁇ 4 ft mM ), in which HER2 / C- erbB-2 positive (+ + +) who achieved complete remission was MUC4 positive and no effect was effective in one case, and MUC4 was negative and there was little effect In one case, treatment was rejected. Both HER2 / C-erbB-2 positive (+ +) were positive for MUC4, and one of them was in early stage because of early stage treatment, but was not treated with trastuzumab (noceptin), but trastuzumab (herceptin) Was a complete remission.
- MUC4 expression and HER2 / C-erbB-2 expression do not always have a parallel relationship.
- MUC4 positive and HER2 / C-erbB-2 positive (+ +) or higher cases show trastuzumab (reactivity to noceptin).
- MUC4 is negative, treatment with trastuzumab (Herceptin was found to be ineffective even with HER2 / c-erbB-2 positive; therefore, combining HER2 / c-erbB-2 with MUC4
- the test showed that the effect of treatment with trastuzumab (Nodiceptin) could be predicted.
- the present invention it is possible to more reliably predict the usefulness of an anticancer drug treatment targeting a receptor for a tumor-associated factor, and to improve the certainty of selecting and selecting subjects to be treated with an anticancer drug. Bring. This will provide an appropriate course of treatment and broaden the scope of application of anticancer drug treatment. Furthermore, it can be expected to have an effect on the medical economy, such as suppressing excessive medication for cancers for which therapeutic effects cannot be expected.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006512299A JPWO2005100983A1 (ja) | 2004-04-16 | 2005-04-05 | 悪性腫瘍の検査方法 |
CA002562304A CA2562304A1 (en) | 2004-04-16 | 2005-04-05 | Method of examining malignant tumor |
AU2005233843A AU2005233843A1 (en) | 2004-04-16 | 2005-04-05 | Method of examining malignant tumor |
US10/599,550 US20070172901A1 (en) | 2004-04-16 | 2005-04-05 | Method for the evaluation of the functional status of the growth factor receptor protein expressed in malignant tumors |
EP05728881A EP1736770A4 (en) | 2004-04-16 | 2005-04-05 | METHOD FOR INVESTIGATING A NICE TUMOR |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-121298 | 2004-04-16 | ||
JP2004121298 | 2004-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005100983A1 true WO2005100983A1 (ja) | 2005-10-27 |
Family
ID=35150119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/006634 WO2005100983A1 (ja) | 2004-04-16 | 2005-04-05 | 悪性腫瘍の検査方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070172901A1 (ja) |
EP (1) | EP1736770A4 (ja) |
JP (1) | JPWO2005100983A1 (ja) |
AU (1) | AU2005233843A1 (ja) |
CA (1) | CA2562304A1 (ja) |
WO (1) | WO2005100983A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009515167A (ja) * | 2005-11-02 | 2009-04-09 | バイエル ヘルスケア エルエルシー | がんの予測及び予後の検査方法、並びにがん治療のモニタリング |
JP2009515166A (ja) * | 2005-11-02 | 2009-04-09 | バイエル ヘルスケア エルエルシー | がんの予測及び予後の検査方法、並びにがん治療のモニタリング |
JP2009519013A (ja) * | 2005-12-05 | 2009-05-14 | アフィボディ・アーベー | ポリペプチド |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100972618B1 (ko) * | 2007-10-19 | 2010-07-27 | 국립암센터 | 허셉틴을 이용한 유방암 진단 키트, 조성물 및 이들을이용하여 허셉틴 민감성 her2 과발현 세포를 검출하는방법 |
US20100280986A1 (en) * | 2009-05-04 | 2010-11-04 | Roche Palo Alto | Systems and methods for tailoring acute and chronic viral infection treatments to increase the probability of "cure" for a given subject |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2710075B1 (fr) * | 1993-09-15 | 1995-10-27 | Bio Merieux | Réactif et procédé pour la détection d'une séquence nucléotidique avec amplification de signal. |
US20020172987A1 (en) * | 1998-02-12 | 2002-11-21 | Terstappen Leon W.M.M. | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
CN102698265A (zh) * | 2000-05-19 | 2012-10-03 | 杰南技术公司 | 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
-
2005
- 2005-04-05 JP JP2006512299A patent/JPWO2005100983A1/ja not_active Withdrawn
- 2005-04-05 AU AU2005233843A patent/AU2005233843A1/en not_active Abandoned
- 2005-04-05 CA CA002562304A patent/CA2562304A1/en not_active Abandoned
- 2005-04-05 WO PCT/JP2005/006634 patent/WO2005100983A1/ja not_active Application Discontinuation
- 2005-04-05 US US10/599,550 patent/US20070172901A1/en not_active Abandoned
- 2005-04-05 EP EP05728881A patent/EP1736770A4/en not_active Withdrawn
Non-Patent Citations (2)
Title |
---|
See also references of EP1736770A4 * |
SHARI A. ET AL: "RAT MUC4 (SIALOMUCIN COMPLEX) REDUCES BINDING OF ANTI-ERBB2 ANTIBODIES TO TUMOR CELL SURFACE, A POTENTIAL MECHANISM FOR HERCEPTIN RESISTANCE.", INTERNATIONAL JOURNAL OF CANCER., vol. 99, 2002, pages 783 - 791, XP002990163 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009515167A (ja) * | 2005-11-02 | 2009-04-09 | バイエル ヘルスケア エルエルシー | がんの予測及び予後の検査方法、並びにがん治療のモニタリング |
JP2009515166A (ja) * | 2005-11-02 | 2009-04-09 | バイエル ヘルスケア エルエルシー | がんの予測及び予後の検査方法、並びにがん治療のモニタリング |
JP2009519013A (ja) * | 2005-12-05 | 2009-05-14 | アフィボディ・アーベー | ポリペプチド |
JP2014087361A (ja) * | 2005-12-05 | 2014-05-15 | Affibody Ab | ポリペプチド |
Also Published As
Publication number | Publication date |
---|---|
AU2005233843A1 (en) | 2005-10-27 |
EP1736770A1 (en) | 2006-12-27 |
JPWO2005100983A1 (ja) | 2008-03-06 |
CA2562304A1 (en) | 2005-10-27 |
EP1736770A4 (en) | 2008-09-24 |
US20070172901A1 (en) | 2007-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Harder et al. | EGFR and HER2 expression in advanced biliary tract cancer | |
Heinmöller et al. | HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin | |
Song et al. | Prognostic significance of AEG-1 expression in colorectal carcinoma | |
Røtterud et al. | Expression of the epidermal growth factor receptor family in normal and malignant urothelium | |
Fichter et al. | EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer | |
Hagiwara et al. | Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer | |
Kawaguchi et al. | Targeting EGFR and HER-2 with cetuximab-and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma | |
Tsofack et al. | Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis | |
Sekaran et al. | HER2 expression in gastric cancer in Indian population—an immunohistochemistry and fluorescence in situ hybridization study | |
Bertagnolli et al. | Canine mammary mixed tumours: Immunohistochemical expressions of EGFR and HER‐2 | |
Li et al. | Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype | |
Kimura et al. | Epidermal growth factor‐dependent enhancement of invasiveness of squamous cell carcinoma of the breast | |
Liang et al. | Expression of ribosome‐binding protein 1 correlates with shorter survival in Her‐2 positive breast cancer | |
Tanase et al. | Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma | |
Yang et al. | C-terminal binding protein-2 promotes cell proliferation and migration in breast cancer via suppression of p16INK4A | |
WO2005100983A1 (ja) | 悪性腫瘍の検査方法 | |
Zhang et al. | Up‐regulation of fibronectin in oesophageal squamous cell carcinoma is associated with activation of the Erk pathway | |
Mathieu et al. | Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer | |
Schlüter et al. | Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer | |
Bánkfalvi et al. | Comparison of automated and manual determination of HER2 status in breast cancer for diagnostic use: a comparative methodological study using the Ventana BenchMark automated staining system and manual tests. | |
Schippinger et al. | The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer | |
Park et al. | Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization | |
Gill et al. | HER-2 involvement in osteosarcoma | |
Alba et al. | HER2 status determination using RNA-ISH-a rapid and simple technique showing high correlation with FISH and IHC in 141 cases of breast cancer | |
Zhao et al. | HER4 is a novel prognostic biomarker in gastrointestinal stromal tumor specifically originated from stomach |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007172901 Country of ref document: US Ref document number: 2562304 Country of ref document: CA Ref document number: 10599550 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005728881 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006512299 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005233843 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005233843 Country of ref document: AU Date of ref document: 20050405 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005233843 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005728881 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10599550 Country of ref document: US |